← Mechanisms of action
Human herpesvirus 4
ORGANISMEpstein-Barr virus (strain GD1) (HHV-4) (Human herpesvirus 4)
Drugs acting on this target (18)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| cmv/ebv specific t-cell | Immunity, active | experimental | Cell therapy | Human herpesvirus 4 immunity, active |
| ebna1 c-terminal/lmp2 chimeric protein-expressing recombinant modified vaccinia ankara vaccine | Immunity, active | experimental | Vaccine | Human herpesvirus 4 immunity, active |
| ebv gp350-ferritin vaccine | Immunity, active | experimental | Vaccine | Human herpesvirus 4 immunity, active |
| mrna-1189 | Immunity, active | experimental | Vaccine | Human herpesvirus 4 immunity, active |
| mva-ebna1/lmp2 vaccine | Immunity, active | experimental | Vaccine | Human herpesvirus 4 immunity, active |
| 14g2a.zeta chimeric receptor transduced autologous ebv specific cytotoxic t-lymphocytes | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| allogeneic epstein-barr virus specific cytotoxic t-lymphocytes | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| autologous epstein-barr virus-specific cytotoxic t lymphocytes | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| cmv/adv /ebv/bkv specific t cells | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| dnr.npc-specific t cells | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| donor-derived ebv-specific cytotoxic t-cells transduced with the retroviral vector sfgalpha-cd19-cd3zeta | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| eb-vst cells | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| ebv vaccine (268664) | Immunity, passive | experimental | Vaccine | Human herpesvirus 4 immunity, passive |
| ebv-lmp-2 | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| epstein-barr virus specific white blood cells | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| tabelecleucel | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| trivirus specific ctls for ebv, cmv and adenovirus infection | Immunity, passive | experimental | Cell therapy | Human herpesvirus 4 immunity, passive |
| valomaciclovir stearate | Inhibitor | experimental | Small molecule | Human herpesvirus 4 inhibitor |